Eventide Healthcare & Life Sciences Fund Class A Shares (ETAHX)

Fund Assets	1.65B
Expense Ratio	1.589%
Min. Investment	$1,000
Turnover	87.00%
Dividend (ttm)	n/a
Dividend Yield	n/a
Dividend Growth	n/a
Payout Frequency	n/a
Ex-Dividend Date	n/a

Previous Close	47.95
YTD Return	-2.80%
1-Year Return	18.94%
5-Year Return	13.78%
52-Week Low	41.66
52-Week High	60.18
Beta (5Y)	0.97
Holdings	93
Inception Date	Dec 27, 2012

About ETAHX

Eventide Healthcare & Life Sciences Fund Class A is an actively managed sector equity fund focused on healthcare and life sciences. Its primary purpose is to provide long-term capital appreciation by investing in companies that demonstrate ethical, sustainable business practices and offer attractive investment opportunities. The fund concentrates on biotechnology, pharmaceuticals, and other healthcare-related sectors, aligning with values-driven investment strategies. It plays a significant role in the financial market by offering investors a specialized portfolio that targets cutting-edge healthcare solutions. The fund's approach is distinguished by its emphasis on early-stage companies, including biotech firms and specialty drug developers, which positions it as a high-risk, high-reward option within its niche.

• Fund Family: Eventide Funds
• Category: Health
• Performance Rating: Average
• Risk Rating: High
• Stock Exchange: Nasdaq
• Ticker Symbol: ETAHX
• Share Class: Class A Shares
• Index: S&P Biotechnology Select Industry TR

Performance

ETAHX had a total return of 18.94% in the past year, including dividends. Since the fund's inception, the average annual return has been 14.10%.

Other Share Classes

These are alternative share classes of the same fund, from the same provider.

Symbol	Share Class	Expense Ratio
ETIHX	Class I Shares	1.31%
ETNHX	Class N Shares	1.51%
ETCHX	Class C Shares	2.31%

Top 10 Holdings

32.42% of assets

Name	Symbol	Weight
Guardant Health, Inc.	GH	5.37%
US BANK MMDA - USBGFS 9	n/a	3.75%
Mirum Pharmaceuticals, Inc.	MIRM	3.47%
Kymera Therapeutics, Inc.	KYMR	3.22%
ABIVAX Société Anonyme	ABVX	2.94%
BELITE BIO INC	n/a	2.83%
Trevi Therapeutics, Inc.	TRVI	2.77%
MBX Biosciences, Inc.	MBX	2.70%
Vaxcyte, Inc.	PCVX	2.69%
Cytokinetics, Incorporated	CYTK	2.69%

Data Sources: Tiingo, Financial Modeling Prep, and more

Historical data is provided by Tiingo. Delayed stock pricing data is provided by Financial Modeling Prep. Several fund data points are also provided by Finnhub.

Last checked:

Oct 16, 2026

Data Sources Report a data error